Suggested remit: To appraise the clinical and cost effectiveness of netarsudil-latanoprost within its marketing authorisation for treating open-angle glaucoma or ocular hypertension.
 
Status Awaiting development
Decision None selected
Process STA 2018
ID number 1363

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
13 January 2022 Please note that following on from information received from the company the timelines for this appraisal are to be confirmed. NICE will continue to monitor the situation and will update interested parties as and when the situation changes.
08 November 2021 - 06 December 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
28 September 2020 - 26 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual